{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T03:56:58Z","timestamp":1785470218539,"version":"3.56.0"},"reference-count":88,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2016,2,18]],"date-time":"2016-02-18T00:00:00Z","timestamp":1455753600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1007\/s12020-016-0888-7","type":"journal-article","created":{"date-parts":[[2016,2,18]],"date-time":"2016-02-18T20:30:37Z","timestamp":1455827437000},"page":"414-426","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["From disease to treatment: from rare skeletal disorders to treatments for osteoporosis"],"prefix":"10.1007","volume":"52","author":[{"given":"Natasha M.","family":"Appelman-Dijkstra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Socrates E.","family":"Papapoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,2,18]]},"reference":[{"issue":"4","key":"888_CR1","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S0092-8674(01)00571-2","volume":"107","author":"Y Gong","year":"2001","unstructured":"Y. Gong, R.B. Slee, N. Fukai, G. Rawadi, S. Roman-Roman, A.M. Reginato, H. Wang, T. Cundy, F.H. Glorieux, D. Lev, M. Zacharin, K. Oexle, J. Marcelino, W. Suwairi, S. Heeger, G. Sabatakos, S. Apte, W.N. Adkins, J. Allgrove, M. Arslan-Kirchner, J.A. Batch, P. Beighton, G.C. Black, R.G. Boles, L.M. Boon, C. Borrone, H.G. Brunner, G.F. Carle, B. Dallapiccola, Paepe A. De, B. Floege, M.L. Halfhide, B. Hall, R.C. Hennekam, T. Hirose, A. Jans, H. J\u00fcppner, C.A. Kim, K. Keppler-Noreuil, A. Kohlschuetter, D. LaCombe, M. Lambert, E. Lemyre, T. Letteboer, L. Peltonen, R.S. Ramesar, M. Romanengo, H. Somer, E. Steichen-Gersdorf, B. Steinmann, B. Sullivan, A. Superti-Furga, W. Swoboda, M.J. Van der Boogaard, W. Van Hul, M. Vikkula, M. Votruba, B. Zabel, T. Garcia, R. Baron, B.R. Olsen, M.L. Warman, Osteoporosis-Pseudoglioma Syndrome Collaborative Group, LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell 107(4), 513\u2013523 (2001)","journal-title":"Cell"},{"issue":"20","key":"888_CR2","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa013444","volume":"346","author":"LM Boyden","year":"2002","unstructured":"L.M. Boyden, J. Mao, J. Belsky, L. Mitzner, A. Farhi, M.A. Mitnick, D. Wu, K. Insogna, R.P. Lifton, High bone density due to a mutation in ldl-receptor-related protein 5. N. Engl. J. Med. 346(20), 1513\u20131521 (2002)","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"888_CR3","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1086\/338450","volume":"70","author":"RD Little","year":"2002","unstructured":"R.D. Little, J.P. Carulli, R.G. Del Mastro, J. Dupuis, M. Osborne, C. Folz, S.P. Manning, P.M. Swain, S.C. Zhao, B. Eustace, M.M. Lappe, L. Spitzer, S. Zweier, K. Braunschweiger, Y. Benchekroun, X. Hu, R. Adair, L. Chee, M.G. FitzGerald, C. Tulig, A. Caruso, N. Tzellas, A. Bawa, B. Franklin, S. McGuire, X. Nogues, G. Gong, K.M. Allen, A. Anisowicz, A.J. Morales, P.T. Lomedico, S.M. Recker, P. Van Eerdewegh, R.R. Recker, M.L. Johnson, A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait. Am. J. Hum. Genet. 70(1), 11\u201319 (2002)","journal-title":"Am. J. Hum. Genet."},{"issue":"4","key":"888_CR4","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1359\/jbmr.070109","volume":"22","author":"MA Karsdal","year":"2007","unstructured":"M.A. Karsdal, T.J. Martin, J. Bollerslev, C. Christiansen, K. Henriksen, Are nonresorbing osteoclasts sources of bone anabolic activity? J. Bone Miner. Res. 22(4), 487\u2013494 (2007)","journal-title":"J. Bone Miner. Res."},{"issue":"6","key":"888_CR5","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.beem.2014.07.003","volume":"28","author":"NM Appelman-Dijkstra","year":"2014","unstructured":"N.M. Appelman-Dijkstra, S.E. Papapoulos, Novel approaches to the treatment of osteoporosis. Best Pract. Res. Clin. Endocrinol. Metab. 28(6), 843\u2013857 (2014)","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"key":"888_CR6","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.coph.2014.03.004","volume":"16","author":"KW Ng","year":"2014","unstructured":"K.W. Ng, T.J. Martin, New therapeutics for osteoporosis. Curr. Opin. Pharmacol. 16, 58\u201363 (2014)","journal-title":"Curr. Opin. Pharmacol."},{"key":"888_CR7","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1517\/17460441.2014.884067","volume":"9","author":"P Schwarz","year":"2014","unstructured":"P. Schwarz, N.R. J\u00f8rgensen, B. Abrahamsen, Status of drug development for the prevention and treatment of osteoporosis. Expert Opin. Drug Discov. 9, 245\u2013253 (2014)","journal-title":"Expert Opin. Drug Discov."},{"key":"888_CR8","first-page":"267","volume":"19","author":"P Maroteaux","year":"1962","unstructured":"P. Maroteaux, Y.M. Lamy, 2 cases of a condensing osseous disease: pynodysostosis. Arch Fr. Pediatr. 19, 267\u2013274 (1962)","journal-title":"Arch Fr. Pediatr."},{"key":"888_CR9","first-page":"999","volume":"70","author":"P Maroteaux","year":"1962","unstructured":"P. Maroteaux, Y.M. Lamy, Pyknodysostosis. Presse Med. 70, 999\u20131002 (1962)","journal-title":"Presse Med."},{"key":"888_CR10","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/1750-1172-9-60","volume":"9","author":"A Arman","year":"2014","unstructured":"A. Arman, A. Bereket, A. Coker, P.\u00d6. Kiper, T. G\u00fcran, B. Ozkan, Z. Atay, T. Ak\u00e7ay, B. Haliloglu, K. Boduroglu, Y. Alanay, S. Turan, Cathepsin K analysis in a pycnodysostosis cohort: demographic, genotypic and phenotypic features. Orphanet. J. Rare Dis. 9, 60 (2014)","journal-title":"Orphanet. J. Rare Dis."},{"key":"888_CR11","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1359\/jbmr.080231","volume":"23","author":"P Chavassieux","year":"2008","unstructured":"P. Chavassieux, M. Asser Karsdal, T. Segovia-Silvestre, A.V. Neutzsky-Wulff, R. Chapurlat, G. Boivin, P.D. Delmas, Mechanisms of the anabolic effects of teriparatide on bone: insight from the treatment of a patient with pycnodysostosis. J. Bone Miner. Res. 23, 1076\u20131083 (2008)","journal-title":"J. Bone Miner. Res."},{"key":"888_CR12","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1210\/jc.2003-031055","volume":"89","author":"N Fratzl-Zelman","year":"2004","unstructured":"N. Fratzl-Zelman, A. Valenta, P. Roschger, A. Nader, B.D. Gelb, P. Fratzl, K. Klaushofer, Decreased bone turnover and deterioration of bone structure in two cases of pycnodysostosis. J. Clin. Endocrinol. Metab. 89, 1538\u20131547 (2004)","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"2","key":"888_CR13","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/ng0695-235","volume":"10","author":"BD Gelb","year":"1995","unstructured":"B.D. Gelb, J.G. Edelson, R.J. Desnick, Linkage of pycnodysostosis to chromosome 1q21 by homozygosity mapping. Nat. Genet. 10(2), 235\u2013237 (1995)","journal-title":"Nat. Genet."},{"issue":"4","key":"888_CR14","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1074\/jbc.271.4.2126","volume":"271","author":"D Br\u00f6mme","year":"1996","unstructured":"D. Br\u00f6mme, K. Okamoto, B.B. Wang, S. Biroc, Human cathepsin O2, a matrix protein-degrading cysteine protease expressed in osteoclasts. Functional expression of human cathepsin O2 in spodoptera frugiperda and characterization of the enzyme. J. Biol. Chem. 271(4), 2126\u20132132 (1996)","journal-title":"J. Biol. Chem."},{"issue":"21","key":"888_CR15","doi-asserted-by":"crossref","first-page":"12517","DOI":"10.1074\/jbc.271.21.12517","volume":"271","author":"MJ Bossard","year":"1996","unstructured":"M.J. Bossard, T.A. Tomaszek, S.K. Thompson, B.Y. Amegadzie, C.R. Hanning, C. Jones, J.T. Kurdyla, D.E. McNulty, F.H. Drake, M. Gowen, M.A. Levy, Proteolytic activity of human osteoclast cathepsin K. Expression, purification, activation, and substrate identification. J. Biol. Chem. 271(21), 12517\u201312524 (1996)","journal-title":"J. Biol. Chem."},{"key":"888_CR16","doi-asserted-by":"crossref","first-page":"12511","DOI":"10.1074\/jbc.271.21.12511","volume":"271","author":"FH Drake","year":"1996","unstructured":"F.H. Drake, R.A. Dodds, I.E. James, J.R. Connor, C. Debouck, S. Richardson, E. Lee-Rykaczewski, L. Coleman, D. Rieman, R. Barthlow, G. Hastings, M. Gowen, Cathepsin K, but not cathepsins B, L, or S, is abundantly expressed in human osteoclasts. J. Biol. Chem. 271, 12511\u201312516 (1996)","journal-title":"J. Biol. Chem."},{"key":"888_CR17","doi-asserted-by":"crossref","first-page":"32347","DOI":"10.1074\/jbc.273.48.32347","volume":"273","author":"P Garnero","year":"1998","unstructured":"P. Garnero, O. Borel, I. Byrjalsen, M. Ferreras, F.H. Drake, M.S. McQueney, N.T. Foged, P.D. Delmas, J.M. Delaiss\u00e9, The collagenolytic activity of cathepsin K is unique among mammalian proteinases. J. Biol. Chem. 273, 32347\u201332352 (1998)","journal-title":"J. Biol. Chem."},{"issue":"6","key":"888_CR18","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1038\/nri1110","volume":"3","author":"K Honey","year":"2003","unstructured":"K. Honey, A.Y. Rudensky, Lysosomal cysteine proteases regulate antigen presentation. Nat Rev Immunol 3(6), 472\u2013482 (2003)","journal-title":"Nat Rev Immunol"},{"key":"888_CR19","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/S8756-3282(98)00138-0","volume":"23","author":"T Yamaza","year":"1998","unstructured":"T. Yamaza, T. Goto, T. Kamiya, Y. Kobayashi, H. Sakai, T. Tanaka, Study of immunoelectron microscopic localization of cathepsin K in osteoclasts and other bone cells in the mouse femur. Bone 23, 499\u2013509 (1998)","journal-title":"Bone"},{"key":"888_CR20","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1359\/JBMR.040603","volume":"19","author":"J V\u00e4\u00e4r\u00e4niemi","year":"2004","unstructured":"J. V\u00e4\u00e4r\u00e4niemi, J.M. Halleen, K. Kaarlonen, H. Ylipahkala, S.L. Alatalo, G. Andersson, H. Kaija, P. Vihko, H.K. V\u00e4\u00e4n\u00e4nen, Intracellular machinery for matrix degradation in bone-resorbing osteoclasts. J. Bone Miner. Res. 19, 1432\u20131440 (2004)","journal-title":"J. Bone Miner. Res."},{"key":"888_CR21","first-page":"679","volume":"380","author":"L Xia","year":"1999","unstructured":"L. Xia, J. Kilb, H. Wex, Z. Li, A. Lipyansky, V. Breuil, L. Stein, J.T. Palmer, D.W. Dempster, D. Br\u00f6mme, Localization of rat cathepsin K in osteoclasts and resorption pits: inhibition of bone resorption and cathepsin k-activity by peptidyl vinyl sulfones. Biol. Chem. 380, 679\u2013687 (1999)","journal-title":"Biol. Chem."},{"key":"888_CR22","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1359\/jbmr.1999.14.11.1902","volume":"14","author":"Y Nishi","year":"1999","unstructured":"Y. Nishi, L. Atley, D.E. Eyre, J.G. Edelson, A. Superti-Furga, T. Yasuda, R.J. Desnick, B.D. Gelb, Determination of bone markers in pycnodysostosis: effects of cathepsin K deficiency on bone matrix degradation. J. Bone Miner. Res. 14, 1902\u20131908 (1999)","journal-title":"J. Bone Miner. Res."},{"key":"888_CR23","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1359\/jbmr.1999.14.10.1654","volume":"14","author":"M Gowen","year":"1999","unstructured":"M. Gowen, F. Lazner, R. Dodds, R. Kapadia, J. Feild, M. Tavaria, I. Bertoncello, F. Drake, S. Zavarselk, I. Tellis, P. Hertzog, C. Debouck, I. Kola, Cathepsin K knockout mice develop osteopetrosis due to a deficit in matrix degradation but not demineralization. J. Bone Miner. Res. 14, 1654\u20131663 (1999)","journal-title":"J. Bone Miner. Res."},{"key":"888_CR24","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1359\/jbmr.2001.16.8.1444","volume":"16","author":"R Kiviranta","year":"2001","unstructured":"R. Kiviranta, J. Morko, H. Uusitalo, H.T. Aro, E. Vuorio, J. Rantakokko, Accelerated turnover of metaphyseal trabecular bone in mice overexpressing cathepsin K. J. Bone Miner. Res. 16, 1444\u20131452 (2001)","journal-title":"J. Bone Miner. Res."},{"key":"888_CR25","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.bone.2008.08.130","volume":"44","author":"B Pennypacker","year":"2009","unstructured":"B. Pennypacker, M. Shea, Q. Liu, P. Masarachia, P. Saftig, S. Rodan, G. Rodan, D. Kimmel, Bone density, strength, and formation in adult cathepsin K (-\/-) mice. Bone 44, 199\u2013207 (2009)","journal-title":"Bone"},{"key":"888_CR26","first-page":"666","volume":"123","author":"S Lotinun","year":"2013","unstructured":"S. Lotinun, R. Kiviranta, T. Matsubara, J.A. Alzate, L. Neff, A. L\u00fcth, I. Koskivirta, B. Kleuser, J. Vacher, E. Vuorio, W.C. Horne, R. Baron, Osteoclast-specific cathepsin K deletion stimulates s1p-dependent bone formation. J. Clin. Invest. 123, 666\u2013681 (2013)","journal-title":"J. Clin. Invest."},{"key":"888_CR27","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.bone.2007.09.044","volume":"42","author":"K Fuller","year":"2008","unstructured":"K. Fuller, K.M. Lawrence, J.L. Ross, U.B. Grabowska, M. Shiroo, B. Samuelsson, T.J. Chambers, Cathepsin K inhibitors prevent matrix-derived growth factor degradation by human osteoclasts. Bone 42, 200\u2013211 (2008)","journal-title":"Bone"},{"key":"888_CR28","first-page":"3915","volume":"7","author":"M Valdes-Flores","year":"2014","unstructured":"M. Valdes-Flores, A. Hidalgo-Bravo, L. Casas-Avila, C. Chima-Galan, E.J. Hazan-Lasri, E. Pineda-Gomez, D. Lopez-Estrada, J.C. Zenteno, Molecular and clinical analysis in a series of patients with pyknodysostosis reveals some uncommon phenotypic findings. Int. J. Clin. Exp. Med. 7, 3915\u20133923 (2014)","journal-title":"Int. J. Clin. Exp. Med."},{"key":"888_CR29","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1750-1172-6-20","volume":"6","author":"Y Xue","year":"2011","unstructured":"Y. Xue, T. Cai, S. Shi, W. Wang, Y. Zhang, T. Mao, X. Duan, Clinical and animal research findings in pycnodysostosis and gene mutations of cathepsin K from 1996 to 2011. Orphanet J Rare Dis 6, 20 (2011)","journal-title":"Orphanet J Rare Dis"},{"key":"888_CR30","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s00198-006-0311-y","volume":"18","author":"AF Schilling","year":"2007","unstructured":"A.F. Schilling, C. M\u00fclhausen, W. Lehmann, R. Santer, T. Schinke, J.M. Rueger, M. Amling, High bone mineral density in pycnodysostotic patients with a novel mutation in the propeptide of cathepsin K. Osteoporos. Int. 18, 659\u2013669 (2007)","journal-title":"Osteoporos. Int."},{"key":"888_CR31","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s11914-011-0085-9","volume":"10","author":"S Boonen","year":"2012","unstructured":"S. Boonen, E. Rosenberg, F. Claessens, D. Vanderschueren, S. Papapoulos, Inhibition of cathepsin K for treatment of osteoporosis. Curr. Osteoporos. Rep. 10, 73\u201379 (2012)","journal-title":"Curr. Osteoporos. Rep."},{"key":"888_CR32","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1002\/jbmr.1477","volume":"27","author":"T Cusick","year":"2012","unstructured":"T. Cusick, C.M. Chen, B.L. Pennypacker, M. Pickarski, D.B. Kimmel, B.B. Scott, T. le Duong, Odanacatib treatment increases hip bone mass and cortical thickness by preserving endocortical bone formation and stimulating periosteal bone formation in the ovariectomized adult rhesus monkey. J. Bone Miner. Res. 27, 524\u2013537 (2012)","journal-title":"J. Bone Miner. Res."},{"key":"888_CR33","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1007\/s00223-009-9279-x","volume":"85","author":"GB Stroup","year":"2009","unstructured":"G.B. Stroup, S. Kumar, C.P. Jerome, Treatment with a potent cathepsin K inhibitor preserves cortical and trabecular bone mass in ovariectomized monkeys. Calcif. Tissue Int. 85, 344\u2013355 (2009)","journal-title":"Calcif. Tissue Int."},{"key":"888_CR34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bone.2014.04.023","volume":"65","author":"Y Ochi","year":"2014","unstructured":"Y. Ochi, H. Yamada, H. Mori, Y. Nakanishi, S. Nishikawa, R. Kayasuga, N. Kawada, A. Kunishige, Y. Hashimoto, M. Tanaka, M. Sugitani, K. Kawabata, Effects of eight-month treatment with ONO-5334, a cathepsin K inhibitor, on bone metabolism, strength and microstructure in ovariectomized cynomolgus monkeys. Bone 65, 1\u20138 (2014)","journal-title":"Bone"},{"key":"888_CR35","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1002\/jbmr.2211","volume":"29","author":"BL Pennypacker","year":"2014","unstructured":"B.L. Pennypacker, C.M. Chen, H. Zheng, M.S. Shih, M. Belfast, R. Samadfam, T. le Duong, Inhibition of cathepsin K increases modeling-based bone formation, and improves cortical dimension and strength in adult ovariectomized monkeys. J. Bone Miner. Res. 29, 1847\u20131858 (2014)","journal-title":"J. Bone Miner. Res."},{"key":"888_CR36","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s00198-011-1593-2","volume":"23","author":"C Jerome","year":"2012","unstructured":"C. Jerome, M. Missbach, R. Gamse, Balicatib, a cathepsin K inhibitor, stimulates periosteal bone formation in monkeys. Osteoporos. Int. 23, 339\u2013349 (2012)","journal-title":"Osteoporos. Int."},{"key":"888_CR37","doi-asserted-by":"crossref","first-page":"4329","DOI":"10.1210\/jc.2013-2630","volume":"98","author":"TJ Chambers","year":"2013","unstructured":"T.J. Chambers, J.H. Tobias, Are cathepsin K inhibitors just another class of antiresorptives? J. Clin. Endocrinol. Metab. 98, 4329\u20134331 (2013)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"888_CR38","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1097\/00003086-197101000-00035","volume":"74","author":"P Sarnsethsiri","year":"1971","unstructured":"P. Sarnsethsiri, O.K. Hitt, E.J. Eyring, H.M. Frost, Tetracycline-based study of bone dynamics in pycnodysostosis. Clin. Orthop. Relat. Res. 74, 301\u2013312 (1971)","journal-title":"Clin. Orthop. Relat. Res."},{"key":"888_CR39","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1002\/jbmr.223","volume":"26","author":"BL Pennypacker","year":"2011","unstructured":"B.L. Pennypacker, L.T. Duong, T.E. Cusick, P.J. Masarachia, M.A. Gentile, J.Y. Gauthier, W.C. Black, B.B. Scott, R. Samadfam, S.Y. Smith, D.B. Kimmel, Cathepsin K inhibitors prevent bone loss in estrogen-deficient rabbits. J. Bone Miner. Res. 26, 252\u2013262 (2011)","journal-title":"J. Bone Miner. Res."},{"key":"888_CR40","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1186\/1471-2474-14-344","volume":"14","author":"BL Pennypacker","year":"2013","unstructured":"B.L. Pennypacker, R.M. Oballa, S. Levesque, D.B. Kimmel, T. le Duong, Cathepsin K inhibitors increase distal femoral bone mineral density in rapidly growing rabbits. BMC Musculoskelet Disord 14, 344 (2013)","journal-title":"BMC Musculoskelet Disord"},{"issue":"1","key":"888_CR41","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/jor.22982","volume":"34","author":"BL Pennypacker","year":"2016","unstructured":"B.L. Pennypacker, D. Gilberto, N.T. Gatto, R. Samadfam, S.Y. Smith, D.B. Kimmel, Thi Duong L. Odanacatib increases mineralized callus during fracture healing in a rabbit ulnar osteotomy model. J. Orthop. Res. 34(1), 72\u201380 (2016)","journal-title":"J. Orthop. Res."},{"key":"888_CR42","author":"MP Khan","year":"2015","unstructured":"M.P. Khan, A.K. Singh, A.K. Singh, P. Shrivastava, M.C. Tiwari, G.K. Nagar, H.K. Bora, V. Parameswaran, S. Sanyal, J.R. Bellare, N. Chattopadhyay, Odanacatib restores trabecular bone of skeletally mature female rabbits with osteopenia but induces brittleness of cortical bone: a comparative study of the investigational drug with PTH, estrogen, and alendronate. J. Bone Miner. Res. (2015). doi: 10.1002\/jbmr.2719","journal-title":"J. Bone Miner. Res."},{"key":"888_CR43","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1359\/jbmr.091035","volume":"25","author":"HG Bone","year":"2010","unstructured":"H.G. Bone, M.R. McClung, C. Roux, R.R. Recker, J.A. Eisman, N. Verbruggen, C.M. Hustad, C. DaSilva, A.C. Santora, B.A. Ince, Odanacatib, a cathepsin-k inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density. J. Bone Miner. Res. 25, 937\u2013947 (2010)","journal-title":"J. Bone Miner. Res."},{"key":"888_CR44","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1002\/jbmr.1695","volume":"27","author":"B Langdahl","year":"2012","unstructured":"B. Langdahl, N. Binkley, H. Bone, N. Gilchrist, H. Resch, J. Rodriguez Portales, A. Denker, A. Lombardi, C. Le Bailly De Tilleghem, C. Dasilva, E. Rosenberg, A. Leung, Odanacatib in the treatment of postmenopausal women with low bone mineral density: five years of continued therapy in a phase 2 study. J. Bone Miner. Res. 27, 2251\u20132258 (2012)","journal-title":"J. Bone Miner. Res."},{"key":"888_CR45","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1002\/jbmr.2047","volume":"29","author":"R Eastell","year":"2014","unstructured":"R. Eastell, S. Nagase, M. Small, S. Boonen, T. Spector, M. Ohyama, T. Kuwayama, S. Deacon, Effect of ONO-5334 on bone mineral density and biochemical markers of bone turnover in postmenopausal osteoporosis: 2-year results from the OCEAN study. J. Bone Miner. Res. 29, 458\u2013466 (2014)","journal-title":"J. Bone Miner. Res."},{"issue":"2","key":"888_CR46","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1210\/jc.2012-2972","volume":"98","author":"K Brixen","year":"2013","unstructured":"K. Brixen, R. Chapurlat, A.M. Cheung, T.M. Keaveny, T. Fuerst, K. Engelke, R. Recker, B. Dardzinski, N. Verbruggen, S. Ather, E. Rosenberg, A.E. de Papp, Bone density, turnover, and estimated strength in postmenopausal women treated with odanacatib: a randomized trial. J. Clin. Endocrinol. Metab. 98(2), 571\u2013580 (2013)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"888_CR47","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1002\/jbmr.2194","volume":"29","author":"AM Cheung","year":"2014","unstructured":"A.M. Cheung, S. Majumdar, K. Brixen, R. Chapurlat, T. Fuerst, K. Engelke, B. Dardzinski, A. Cabal, N. Verbruggen, S. Ather, E. Rosenberg, A.E. de Papp, Effects of odanacatib on the radius and tibia of postmenopausal women: improvements in bone geometry, microarchitecture, and estimated bone strength. J. Bone Miner. Res. 29, 1786\u20131794 (2014)","journal-title":"J. Bone Miner. Res."},{"key":"888_CR48","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1002\/jbmr.2292","volume":"30","author":"K Engelke","year":"2015","unstructured":"K. Engelke, T. Fuerst, B. Dardzinski, J. Kornak, S. Ather, H.K. Genant, A. de Papp, Odanacatib treatment affects trabecular and cortical bone in the femur of postmenopausal women: results of a two-year placebo-controlled trial. J. Bone Miner. Res. 30, 30\u201338 (2015)","journal-title":"J. Bone Miner. Res."},{"key":"888_CR49","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s00198-014-2944-6","volume":"26","author":"HG Bone","year":"2015","unstructured":"H.G. Bone, D.W. Dempster, J.A. Eisman, S.L. Greenspan, M.R. McClung, T. Nakamura, S. Papapoulos, W.J. Shih, A. Rybak-Feiglin, A.C. Santora, N. Verbruggen, A.T. Leung, A. Lombardi, Odanacatib for the treatment of postmenopausal osteoporosis: development history and design and participant characteristics of LOFT, the long-term odanacatib fracture trial. Osteoporos. Int. 26, 699\u2013712 (2015)","journal-title":"Osteoporos. Int."},{"key":"888_CR50","unstructured":"M. McClung, B. Langdahl, S. Papapoulos, K. Saag, S. Adami, H. Bone, A. Rybak-Feiglin, D. Cohn, C.A. DaSilva, R. Massaad, A.C. Santora, B.B. Scott, K.D. Kaufman, N. Verbruggen, A. Leung, A. Lombardi. Odanacatib anti-fracture efficacy and safety in postmenopausal women with osteoporosis. Results from the phase III long-term odanacatib fracture trial (LOFT). IBMS BoneKEy 13, Article number: 677 (2015)"},{"issue":"2","key":"888_CR51","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1302\/0301-620X.40B2.208","volume":"40-B","author":"AS Truswell","year":"1958","unstructured":"A.S. Truswell, Osteopetrosis with syndactyly; a morphological variant of Albers-Sch\u00f6nberg\u2019s disease. J. Bone Joint Surg. Br. 40-B(2), 209\u2013218 (1958)","journal-title":"J. Bone Joint Surg. Br."},{"key":"888_CR52","first-page":"351","volume-title":"Handbuch der Kinderheilkunde","author":"HG Hansen","year":"1967","unstructured":"H.G. Hansen, Sklerosteose, in Handbuch der Kinderheilkunde, vol. 6, ed. by J. Opitz, F. Schmid (Springer, Berlin, 1967), pp. 351\u2013355"},{"key":"888_CR53","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.1002\/jbmr.474","volume":"26","author":"AH Lierop van","year":"2011","unstructured":"A.H. van Lierop, N.A. Hamdy, H. Hamersma, R.L. van Bezooijen, J. Power, N. Loveridge, S.E. Papapoulos, Patients with sclerosteosis and disease carriers: human models of the effect of sclerostin on bone turnover. J. Bone Miner. Res. 26, 2804\u20132811 (2011)","journal-title":"J. Bone Miner. Res."},{"issue":"12","key":"888_CR54","doi-asserted-by":"crossref","first-page":"6392","DOI":"10.1210\/jc.2005-1235","volume":"90","author":"JC Gardner","year":"2005","unstructured":"J.C. Gardner, R.L. van Bezooijen, B. Mervis, N.A. Hamdy, C.W. L\u00f6wik, H. Hamersma, P. Beighton, S.E. Papapoulos, Bone mineral density in sclerosteosis; affected individuals and gene carriers. J. Clin. Endocrinol. Metab. 90(12), 6392\u20136395 (2005)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"888_CR55","doi-asserted-by":"crossref","first-page":"393","DOI":"10.7326\/0003-4819-84-4-393","volume":"84","author":"P Beighton","year":"1976","unstructured":"P. Beighton, L. Durr, H. Hamersma, The clinical features of sclerosteosis. A review of the manifestations in twenty-five affected individuals. Ann. Intern. Med. 84, 393\u2013397 (1976)","journal-title":"Ann. Intern. Med."},{"key":"888_CR56","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1212\/WNL.33.3.267","volume":"33","author":"SA Stein","year":"1983","unstructured":"S.A. Stein, C. Witkop, S. Hill, M.D. Fallon, L. Viernstein, G. Gucer, P. McKeever, D. Long, J. Altman, N.R. Miller, S.L. Teitelbaum, S. Schlesinger, Sclerosteosis: neurogenetic and pathophysiologic analysis of an American kinship. Neurology 33, 267\u2013277 (1983)","journal-title":"Neurology"},{"key":"888_CR57","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1002\/jbmr.2259","volume":"29","author":"N Hassler","year":"2014","unstructured":"N. Hassler, A. Roschger, S. Gamsjaeger, I. Kramer, S. Lueger, A. van Lierop, P. Roschger, K. Klaushofer, E.P. Paschalis, M. Kneissel, S. Papapoulos, Sclerostin deficiency is linked to altered bone composition. J. Bone Miner. Res. 29, 2144\u20132151 (2014)","journal-title":"J. Bone Miner. Res."},{"key":"888_CR58","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1086\/318811","volume":"68","author":"ME Brunkow","year":"2001","unstructured":"M.E. Brunkow, J.C. Gardner, J. Van Ness, B.W. Paeper, B.R. Kovacevich, S. Proll, J.E. Skonier, L. Zhao, P.J. Sabo, Y. Fu, R.S. Alisch, L. Gillett, T. Colbert, P. Tacconi, D. Galas, H. Hamersma, P. Beighton, J. Mulligan, Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am. J. Hum. Genet. 68, 577\u2013589 (2001)","journal-title":"Am. J. Hum. Genet."},{"issue":"5","key":"888_CR59","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1093\/hmg\/10.5.537","volume":"10","author":"W Balemans","year":"2001","unstructured":"W. Balemans, M. Ebeling, N. Patel, E. Van Hul, P. Olson, M. Dioszegi, C. Lacza, W. Wuyts, J. Van Den Ende, P. Willems, A.F. Paes-Alves, S. Hill, M. Bueno, F.J. Ramos, P. Tacconi, F.G. Dikkers, C. Stratakis, K. Lindpaintner, B. Vickery, D. Foernzler, W. Van Hul, Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum. Mol. Genet. 10(5), 537\u2013543 (2001)","journal-title":"Hum. Mol. Genet."},{"key":"888_CR60","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1084\/jem.20031454","volume":"199","author":"RL Bezooijen van","year":"2004","unstructured":"R.L. van Bezooijen, B.A. Roelen, A. Visser, L. van der Wee-Pals, E. de Wilt, M. Karperien, H. Hamersma, S.E. Papapoulos, P. ten Dijke, C.W. L\u00f6wik, Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist. J. Exp. Med. 199, 805\u2013814 (2004)","journal-title":"J. Exp. Med."},{"issue":"1","key":"888_CR61","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1359\/jbmr.061002","volume":"22","author":"RL Bezooijen van","year":"2007","unstructured":"R.L. van Bezooijen, J.P. Svensson, D. Eefting, A. Visser, G. van der Horst, M. Karperien, P.H. Quax, H. Vrieling, S.E. Papapoulos, P. ten Dijke, C.W. L\u00f6wik, Wnt but not BMP signaling is involved in the inhibitory action of sclerostin on BMP-stimulated bone formation. J. Bone Miner. Res. 22(1), 19\u201328 (2007)","journal-title":"J. Bone Miner. Res."},{"key":"888_CR62","doi-asserted-by":"crossref","first-page":"19489","DOI":"10.1074\/jbc.M110.190330","volume":"286","author":"O Leupin","year":"2011","unstructured":"O. Leupin, E. Piters, C. Halleux, S. Hu, I. Kramer, F. Morvan, T. Bouwmeester, M. Schirle, M. Bueno-Lozano, F.J. Fuentes, P.H. Itin, E. Boudin, F. de Freitas, K. Jennes, B. Brannetti, N. Charara, H. Ebersbach, S. Geisse, C.X. Lu, A. Bauer, W. Van Hul, M. Kneissel, Bone overgrowth-associated mutations in the LRP4 gene impair sclerostin facilitator function. J. Biol. Chem. 286, 19489\u201319500 (2011)","journal-title":"J. Biol. Chem."},{"key":"888_CR63","doi-asserted-by":"crossref","first-page":"E5187","DOI":"10.1073\/pnas.1413828111","volume":"111","author":"MK Chang","year":"2014","unstructured":"M.K. Chang, I. Kramer, T. Huber, B. Kinzel, S. Guth-Gundel, O. Leupin, M. Kneissel, Disruption of Lrp4 function by genetic deletion or pharmacological blockade increases bone mass and serum sclerostin levels. Proc. Natl. Acad. Sci. USA 111, E5187\u2013E5195 (2014)","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"888_CR64","doi-asserted-by":"crossref","first-page":"e25900","DOI":"10.1371\/journal.pone.0025900","volume":"6","author":"AR Wijenayaka","year":"2011","unstructured":"A.R. Wijenayaka, M. Kogawa, H.P. Lim, L.F. Bonewald, D.M. Findlay, G.J. Atkins, Sclerostin stimulates osteocyte support of osteoclast activity by a rankl-dependent pathway. PLoS One 6, e25900 (2011)","journal-title":"PLoS One"},{"issue":"5","key":"888_CR65","doi-asserted-by":"crossref","first-page":"E478","DOI":"10.1073\/pnas.1409857112","volume":"112","author":"X Tu","year":"2015","unstructured":"X. Tu, J. Delgado-Calle, K.W. Condon, M. Maycas, H. Zhang, N. Carlesso, M.M. Taketo, D.B. Burr, L.I. Plotkin, T. Bellido, Osteocytes mediate the anabolic actions of canonical Wnt\/\u03b2-catenin signaling in bone. Proc. Natl. Acad. Sci. USA 112(5), E478\u2013E486 (2015)","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"5","key":"888_CR66","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1002\/jbmr.304","volume":"26","author":"Y Rhee","year":"2011","unstructured":"Y. Rhee, M.R. Allen, K. Condon, V. Lezcano, A.C. Ronda, C. Galli, N. Olivos, G. Passeri, C.A. O\u2019Brien, N. Bivi, L.I. Plotkin, T. Bellido, PTH receptor signaling in osteocytes governs periosteal bone formation and intracortical remodeling. J. Bone Miner. Res. 26(5), 1035\u20131046 (2011)","journal-title":"J. Bone Miner. Res."},{"key":"888_CR67","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1007\/s40265-015-0417-7","volume":"75","author":"NM Appelman-Dijkstra","year":"2015","unstructured":"N.M. Appelman-Dijkstra, S.E. Papapoulos, Modulating bone resorption and bone formation in opposite directions in the treatment of postmenopausal osteoporosis. Drugs 75, 1049\u20131058 (2015)","journal-title":"Drugs"},{"issue":"6","key":"888_CR68","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1359\/jbmr.080216","volume":"23","author":"X Li","year":"2008","unstructured":"X. Li, M.S. Ominsky, Q.T. Niu, N. Sun, B. Daugherty, D. D\u2019Agostin, C. Kurahara, Y. Gao, J. Cao, J. Gong, F. Asuncion, M. Barrero, K. Warmington, D. Dwyer, M. Stolina, S. Morony, I. Sarosi, P.J. Kostenuik, D.L. Lacey, W.S. Simonet, H.Z. Ke, C. Paszty, Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J. Bone Miner. Res. 23(6), 860\u2013869 (2008)","journal-title":"J. Bone Miner. Res."},{"key":"888_CR69","doi-asserted-by":"crossref","first-page":"6267","DOI":"10.1093\/emboj\/cdg599","volume":"22","author":"DG Winkler","year":"2003","unstructured":"D.G. Winkler, M.K. Sutherland, J.C. Geoghegan, C. Yu, T. Hayes, J.E. Skonier, D. Shpektor, M. Jonas, B.R. Kovacevich, K. Staehling-Hampton, M. Appleby, M.E. Brunkow, J.A. Latham, Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J. 22, 6267\u20136276 (2003)","journal-title":"EMBO J."},{"key":"888_CR70","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3109\/00016925509170789","volume":"44","author":"FS Buchem Van","year":"1955","unstructured":"F.S. Van Buchem, H.N. Hadders, R. Ubbens, An uncommon familial systemic disease of the skeleton: hyperostosis corticalis generalisata familiaris. Acta Radiol. 44, 109\u2013120 (1955)","journal-title":"Acta Radiol."},{"key":"888_CR71","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1002\/jbmr.1794","volume":"28","author":"AH Lierop van","year":"2013","unstructured":"A.H. van Lierop, N.A. Hamdy, M.E. van Egmond, E. Bakker, F.G. Dikkers, S.E. Papapoulos, Van Buchem disease: clinical, biochemical, and densitometric features of patients and disease carriers. J. Bone Miner. Res. 28, 848\u2013854 (2013)","journal-title":"J. Bone Miner. Res."},{"key":"888_CR72","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1136\/jmg.39.2.91","volume":"39","author":"W Balemans","year":"2002","unstructured":"W. Balemans, N. Patel, M. Ebeling, E. Van Hul, W. Wuyts, C. Lacza, M. Dioszegi, F.G. Dikkers, P. Hildering, P.J. Willems, J.B. Verheij, K. Lindpaintner, B. Vickery, D. Foernzler, W. Van Hul, Identification of a 52\u00a0kb deletion downstream of the SOST gene in patients with van Buchem disease. J. Med. Genet. 39, 91\u201397 (2002)","journal-title":"J. Med. Genet."},{"key":"888_CR73","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1002\/ajmg.10401","volume":"110","author":"K Staehling-Hampton","year":"2002","unstructured":"K. Staehling-Hampton, S. Proll, B.W. Paeper, L. Zhao, P. Charmley, A. Brown, J.C. Gardner, D. Galas, R.C. Schatzman, P. Beighton, S. Papapoulos, H. Hamersma, Brunkow ME.A 52-kb deletion in the SOST-MEOX1 intergenic region on 17q12-q21 is associated with van Buchem disease in the Dutch population. Am. J. Med. Genet. 110, 144\u2013152 (2002)","journal-title":"Am. J. Med. Genet."},{"issue":"35","key":"888_CR74","doi-asserted-by":"crossref","first-page":"14092","DOI":"10.1073\/pnas.1207188109","volume":"109","author":"NM Collette","year":"2012","unstructured":"N.M. Collette, D.C. Genetos, A.N. Economides, L. Xie, M. Shahnazari, W. Yao, N.E. Lane, R.M. Harland, G.G. Loots, Targeted deletion of Sost distal enhancer increases bone formation and bone mass. Proc. Natl. Acad. Sci. USA 109(35), 14092\u201314097 (2012)","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"888_CR75","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1002\/jbmr.151","volume":"25","author":"AH Lierop van","year":"2010","unstructured":"A.H. van Lierop, N.A. Hamdy, S.E. Papapoulos, Glucocorticoids are not always deleterious for bone. J. Bone Miner. Res. 25, 2796\u20132800 (2010)","journal-title":"J. Bone Miner. Res."},{"key":"888_CR76","doi-asserted-by":"crossref","first-page":"2647","DOI":"10.1002\/jbmr.182","volume":"25","author":"X Li","year":"2010","unstructured":"X. Li, K.S. Warmington, Q.T. Niu, F.J. Asuncion, M. Barrero, M. Grisanti, D. Dwyer, B. Stouch, T.M. Thway, M. Stolina, M.S. Ominsky, P.J. Kostenuik, W.S. Simonet, C. Paszty, H.Z. Ke, Inhibition of sclerostin by monoclonal antibody increases bone formation, bone mass, and bone strength in aged male rats. J. Bone Miner. Res. 25, 2647\u20132656 (2010)","journal-title":"J. Bone Miner. Res."},{"key":"888_CR77","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1002\/jbmr.14","volume":"25","author":"MS Ominsky","year":"2010","unstructured":"M.S. Ominsky, F. Vlasseros, J. Jolette, S.Y. Smith, B. Stouch, G. Doellgast, J. Gong, Y. Gao, J. Cao, K. Graham, B. Tipton, J. Cai, R. Deshpande, L. Zhou, M.D. Hale, D.J. Lightwood, A.J. Henry, A.G. Popplewell, A.R. Moore, M.K. Robinson, D.L. Lacey, W.S. Simonet, C. Paszty, Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength. J. Bone Miner. Res. 25, 948\u2013959 (2010)","journal-title":"J. Bone Miner. Res."},{"key":"888_CR78","doi-asserted-by":"crossref","first-page":"4785","DOI":"10.1210\/en.2013-1905","volume":"155","author":"X Li","year":"2014","unstructured":"X. Li, Q.T. Niu, K.S. Warmington, F.J. Asuncion, D. Dwyer, M. Grisanti, C.Y. Han, M. Stolina, M.J. Eschenberg, P.J. Kostenuik, W.S. Simonet, M.S. Ominsky, H.Z. Ke, Progressive increases in bone mass and bone strength in an ovariectomized rat model of osteoporosis after 26\u00a0weeks of treatment with a sclerostin antibody. Endocrinology 155, 4785\u20134797 (2014)","journal-title":"Endocrinology"},{"key":"888_CR79","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1002\/jbmr.2152","volume":"29","author":"MS Ominsky","year":"2014","unstructured":"M.S. Ominsky, Q.T. Niu, C. Li, X. Li, H.Z. Ke, Tissue-level mechanisms responsible for the increase in bone formation and bone volume by sclerostin antibody. J. Bone Miner. Res. 29, 1424\u20131430 (2014)","journal-title":"J. Bone Miner. Res."},{"key":"888_CR80","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1002\/jbmr.2188","volume":"29","author":"RD Ross","year":"2014","unstructured":"R.D. Ross, L.H. Edwards, A.S. Acerbo, M.S. Ominsky, A.S. Virdi, K. Sena, L.M. Miller, D.R. Sumner, Bone matrix quality after sclerostin antibody treatment. J. Bone Miner. Res. 29, 1597\u20131607 (2014)","journal-title":"J. Bone Miner. Res."},{"key":"888_CR81","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/jbmr.173","volume":"26","author":"D Padhi","year":"2011","unstructured":"D. Padhi, G. Jang, B. Stouch, L. Fang, E. Posvar, Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J. Bone Miner. Res. 26, 19\u201326 (2011)","journal-title":"J. Bone Miner. Res."},{"key":"888_CR82","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1002\/jbmr.2092","volume":"29","author":"J McColm","year":"2014","unstructured":"J. McColm, L. Hu, T. Womack, C.C. Tang, A.Y. Chiang, Single- and multiple-dose randomized studies of blosozumab, a monoclonal antibody against sclerostin, in healthy postmenopausal women. J. Bone Miner. Res. 29, 935\u2013943 (2014)","journal-title":"J. Bone Miner. Res."},{"key":"888_CR83","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1056\/NEJMoa1305224","volume":"370","author":"MR McClung","year":"2014","unstructured":"M.R. McClung, A. Grauer, S. Boonen, M.A. Bolognese, J.P. Brown, A. Diez-Perez, B.L. Langdahl, J.Y. Reginster, J.R. Zanchetta, S.M. Wasserman, L. Katz, J. Maddox, Y.C. Yang, C. Libanati, H.G. Bone, Romosozumab in postmenopausal women with low bone mineral density. N. Engl. J. Med. 370, 412\u2013420 (2014)","journal-title":"N. Engl. J. Med."},{"issue":"Suppl. 1","key":"888_CR84","first-page":"S53 (abstract 1","volume":"29","author":"MR McClung","year":"2014","unstructured":"M.R. McClung, A. Chines, J.P. Brown, A. Diez-Perez, H. Resch, J. Caminis, M. Bolognese, S. Goemaeres, H.G. Bone, J.R. Zanchetta, J. Maddox, O. Rosen, S. Bray, A. Gauer, Effects of 2\u00a0years of treatment with romosozumab followed by 1\u00a0year of denosumab or placebo in postmenopsusal women with low bone mineral density. JBMR 29(Suppl. 1), S53 (abstract 1152) (2014)","journal-title":"JBMR"},{"key":"888_CR85","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1002\/jbmr.2489","volume":"30","author":"CP Recknor","year":"2015","unstructured":"C.P. Recknor, R.R. Recker, C.T. Benson, D.A. Robins, A.Y. Chiang, J. Alam, L. Hu, T. Matsumoto, H. Sowa, J.H. Sloan, R.J. Konrad, B.H. Mitlak, A.A. Sipos, The effect of discontinuing treatment with blosozumab: follow-up results of a phase 2 randomized clinical trial in postmenopausal women with low bone mineral density. J. Bone Miner. Res. 30, 1717\u20131725 (2015)","journal-title":"J. Bone Miner. Res."},{"key":"888_CR86","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/nrendo.2014.214","volume":"11","author":"SE Papapoulos","year":"2015","unstructured":"S.E. Papapoulos, Anabolic bone therapies in 2014: new bone-forming treatments for osteoporosis. Nat. Rev. Endocrinol. 11, 69\u201370 (2015)","journal-title":"Nat. Rev. Endocrinol."},{"key":"888_CR87","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.bone.2011.06.014","volume":"49","author":"P Leung","year":"2011","unstructured":"P. Leung, M. Pickarski, Y. Zhuo, P.J. Masarachia, L.T. Duong, The effects of the cathepsin K inhibitor odanacatib on osteoclastic bone resorption and vesicular trafficking. Bone 49, 623\u2013635 (2011)","journal-title":"Bone"},{"key":"888_CR88","unstructured":"van der Wouden A. Botziekten in het os temporalis met gehoorstoornissen. PhD Thesis, Leiden (1971)"}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-016-0888-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12020-016-0888-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-016-0888-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T12:43:12Z","timestamp":1718368992000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12020-016-0888-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,18]]},"references-count":88,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["888"],"URL":"https:\/\/doi.org\/10.1007\/s12020-016-0888-7","relation":{},"ISSN":["1355-008X","1559-0100"],"issn-type":[{"value":"1355-008X","type":"print"},{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2,18]]}}}